U0005 High‑Throughput SARS‑CoV‑2 NAAT Reimbursement | OpenPayer

Summary & Overview

HCPCS U0005: SARS-CoV-2 High-Throughput Nucleic Acid Amplified Test

HCPCS Level II code U0005 designates high-throughput nucleic acid amplification testing for SARS-CoV-2 (COVID-19) using an amplified probe technique completed within 2 calendar days of specimen collection. Introduced during the COVID-19 public health response, this code captures centralized, high-volume laboratory testing performed by CDC or non-CDC laboratories and is billed in addition to either U0003 or U0004 when those codes apply. Nationally, U0005 matters because it distinguishes rapid, high-throughput molecular testing workflows from standard or point-of-care assays, influencing billing, reporting, and laboratory capacity considerations.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical purpose and operational context, summaries of payer coverage practices and common modifiers, and highlights of relevant policy guidance tied to the COVID-19 response. The publication also outlines service-line implications for clinical laboratories and typical sites of service where U0005 is used. Data not available in the input is noted where payer-specific reimbursement benchmarks or ICD-10 pairings are absent.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareU0005HCPCS Level IISARS-CoV-2COVID-19 testingmolecular diagnosticshigh-throughput laboratorynucleic acid amplificationpublic health labs

Billing Code Overview

HCPCS Level II code U0005 describes infectious agent detection by nucleic acid (DNA or RNA) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (COVID-19) using an amplified probe technique performed with high-throughput technologies and completed within 2 calendar days from the date of specimen collection. The description notes that the test may be performed by CDC or non-CDC laboratories and is billed in addition to either HCPCS Level II code U0003 or U0004 when applicable.

Service type: High-throughput nucleic acid amplification testing for SARS-CoV-2.

Typical site of service: Clinical or public health laboratories and high-throughput testing facilities performing centralized COVID-19 molecular diagnostics.

Clinical & Coding Specifications

Clinical Context

A symptomatic adult presents to a high-throughput reference laboratory after nasopharyngeal swab collection at a community drive-through testing site. The patient reports 2 days of fever, cough, and myalgias with recent close contact to a confirmed COVID-19 case. The clinical workflow begins with specimen collection at the site of service (drive-through, urgent care, or hospital outpatient collection), transport to a central laboratory that uses automated, high-throughput nucleic acid amplification platforms, and prioritized processing to deliver results within two calendar days of specimen collection. The laboratory documents specimen receipt, processes the sample using an amplified probe technique for SARS‑CoV‑2 RNA detection, interprets results, and issues a report to the ordering clinician and public health authorities per local requirements. Billing for the high-throughput, rapid completed test is captured with U0005, reported in addition to U0003 or U0004 when applicable, and may include appropriate modifiers to indicate professional component, technical component, or specific circumstances affecting performance or reimbursement.

Coding Specifications

Modifier	Description	When to Use
`11`

HCPCS K0901: Knee Orthosis, Single Upright, Prefabricated

HCPCS-M1001-PAIN-MANAGEMENT-PLAN-OF-CARE-MODERATE-SEVERE-PAIN

HCPCS Level II M1001: Plan of Care for Moderate to Severe Pain

HCPCS-K1001-ELECTRONIC-POSITIONAL-OSA-TREATMENT-SENSOR

HCPCS K1001: Electronic Positional Obstructive Sleep Apnea Treatment, with Sensor

HCPCS-M1071-ADDITIONAL-SPINE-PROCEDURES-WITH-LUMBAR-DISCECTOMY-LAMINOTOMY

HCPCS Level II M1071: Additional Spine Procedures with Lumbar Discectomy/Laminotomy

HCPCS-LEVEL-II-M1144-LIMITED-CONSULTATIVE-THERAPY-1-2-VISITS

HCPCS Level II M1144: Limited/Consultative Therapy, 1-2 Visits

HCPCS-U0004-SARS-COV-2-HIGH-THROUGHPUT-MOLECULAR-TEST-MULTIPLEX

HCPCS U0004: SARS-CoV-2 High-Throughput Multiplex Molecular Test

HCPCS-C1300-HYPERBARIC-OXYGEN-FULL-BODY-CHAMBER-30MIN

HCPCS C1300: Hyperbaric Oxygen in Full-Body Chamber, per 30 Minutes

HCPCS-M1145-MFN-MODEL-DRUG-ADD-ON-PER-DOSE

HCPCS M1145: MFN Model Drug Add-On Amount, Per Dose

HCPCS-K1002-CRANIAL-ELECTROTHERAPY-STIMULATION-SYSTEM

HCPCS K1002: Cranial Electrotherapy Stimulation System

HCPCS-M0064-PSYCHIATRIC-MEDICATION-MANAGEMENT-BRIEF-OFFICE-VISIT

HCPCS M0064: Brief Psychiatric Medication Management Visit

Showing 1–10 of 16

Taxonomy Code	Specialty	Notes
`207Q00000X`	Infectious Disease	ID clinicians commonly order SARS‑CoV‑2 molecular testing and interpret complex results.
`208000000X`	Pathology	Pathologists oversee laboratory testing, quality control, and result interpretation.
`207L00000X`	Diagnostic Radiology	Radiology may be involved in inpatient diagnostic workflows; included as common ordering specialty in hospital settings.
`363L00000X`	Medical Laboratory	Clinical laboratory personnel and directors performing and validating high-throughput molecular assays.
`207P00000X`	Internal Medicine	Primary care and hospitalist physicians frequently order SARS‑CoV‑2 testing in ambulatory and inpatient settings.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`J12.89`	Other viral pneumonia	SARS‑CoV‑2 infection can present as viral pneumonia; used when clinical pneumonia is suspected and testing is performed.
`J22`	Unspecified acute lower respiratory infection	Used when acute lower respiratory tract infection is suspected and SARS‑CoV‑2 testing is part of the diagnostic workup.
`R05`	Cough	Symptom code frequently used when patients present for SARS‑CoV‑2 testing due to respiratory symptoms.
`R50.9`	Fever, unspecified	Fever is a common indication for COVID‑19 testing and is used diagnostically when ordering the NAAT.
`Z20.822`	Contact with and (suspected) exposure to COVID-19	Used for asymptomatic or symptomatic individuals with known exposure to SARS‑CoV‑2 when testing is performed.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`87635`	Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique	Commonly reported for individual SARS‑CoV‑2 NAATs performed on non-high-throughput platforms; may be billed in workflows where high-throughput add-on `U0005` complements or is an alternative.
`87426`	Infectious agent antigen detection by immunoassay, multiple-step method	May be performed in parallel as a rapid antigen test at point of care prior to confirmatory NAAT in specific clinical workflows.
`99000`	Handling and/or conveyance of specimen for transfer from the physician's office to a laboratory	Used when specimen collection site charges for packaging and shipping to a central laboratory performing `U0005`.
`36415`	Collection of venous blood by venipuncture	Included when blood is collected for ancillary testing or serology in the same encounter, though `U0005` is for respiratory nucleic acid detection.
`99070`	Supplies and materials (eg, bandages, gauze, etc.) provided by the physician over and above those usually included with the office visit	Used when additional supplies for specimen collection or expedited shipping are billed by the collecting facility.

OpenPayer